RESUMEN
BACKGROUND: Colorectal cancer (CRC) is the third most prevalent cancer globally, and liver metastasis (CRLM) is the primary cause of death. Hence, it is essential to discover novel prognostic biomarkers and therapeutic drugs for CRLM. METHODS: This study developed two liver metastasis-associated prognostic signatures based on differentially expressed genes (DEGs) in CRLM. Additionally, we employed an interpretable deep learning model utilizing drug sensitivity databases to identify potential therapeutic drugs for high-risk CRLM patients. Subsequently, in vitro and in vivo experiments were performed to verify the efficacy of these compounds. RESULTS: These two prognostic models exhibited superior performance compared to previously reported ones. Obatoclax, a BCL-2 inhibitor, showed significant differential responses between high and low risk groups classified by prognostic models, and demonstrated remarkable effectiveness in both Transwell assay and CT26 colorectal liver metastasis mouse model. CONCLUSIONS: This study highlights the significance of developing specialized prognostication approaches and investigating effective therapeutic drugs for patients with CRLM. The application of a deep learning drug response model provides a new drug discovery strategy for translational medicine in precision oncology.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Hepáticas , Animales , Ratones , Humanos , Medicina de Precisión , Pronóstico , Neoplasias Hepáticas/genética , Descubrimiento de Drogas , Neoplasias Colorrectales/genéticaRESUMEN
Hydrogel-based flexible supercapacitors possess the merits of highly ionic conductivity and superior power density, but the existence of water limits their application in extreme temperature scenarios. Noticeably, it is a challenge for people to design more extremely temperature adaptable systems for flexible supercapacitors based on hydrogels with a wide temperature region. In this work, a wide-temperature flexible supercapacitor that can operate at -20-80 °C was fabricated by an organohydrogel electrolyte and its combined electrode (also known as an electrode/electrolyte composite). Upon introducing highly hydratable LiCl into an ethylene glycol (EG)/H2 O binary solvent, owing to the ionic hydration effect of LiCl and the hydrogen bond interaction between EG and H2 O molecules, the organohydrogel electrolyte exhibits satisfactory resistance to freezing (freezing point of -113.9 °C), anti-drying capability (78.2 % of weight retention after vacuum drying at 60 °C for 12â h) and excellent ionic conductivity both at room temperature (13.9â mS cm-1 ) and low temperature (6.5â mS cm-1 after 31â days at -20 °C). By using organohydrogel electrolyte as binder, the prepared electrode/electrolyte composite effectively reduces interface impedance and enhances specific capacitance due to the uninterrupted ion transport channels and extended interface contact area. The assembled supercapacitor delivers a specific capacitance of 149â F g-1 , a power density of 160â W kg-1 , and an energy density of 13.24â Wh kg-1 at a current density of 0.2â A g-1 . The initial 100 % capacitance can be maintained after 2000 cycles at 1.0â A g-1 . More importantly, the specific capacitances can be well maintained even at -20 and 80 °C. With other advantages such as excellent mechanical property, the supercapacitor is an ideal power source suitable for various working conditions.
RESUMEN
Aside from antibodies, peptides show great potential as immune checkpoint inhibitors (ICIs) due to several advantages, such as better tumor penetration and lower cost. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint which can induce T cell dysfunction through interaction with its soluble ligand fibrinogen like protein-1 (FGL1). Here, we found that LAG-3 expression was higher than programmed cell death protein 1 (PD-1) in multiple human cancers by TCGA databases, and successfully identified a LAG-3 binding peptide LFP-6 by phage display bio-panning, which specifically blocks the interaction of LAG-3/FGL1 but not LAG-3/MHC-II. Subsequently, d-amino acids were introduced to substitute the N- and C-terminus of LFP-6 to obtain the proteolysis-resistant peptide LFP-D1, which restores T cell function in vitro and inhibits tumor growth in vivo. Further, a bispecific peptide LFOP targeting both PD-1/PD-L1 and LAG-3/FGL1 was designed by conjugating LFP-D1 with PD-1/PD-L1 blocking peptide OPBP-1(8-12), which activates T cell with enhanced proliferation and IFN-γ production. More importantly, LFOP combined with radiotherapy significantly improve the T cell infiltration in tumor and elevate systemic antitumor immune response. In conclusion, we developed a novel peptide blocking LAG-3/FGL1 which can restore T cell function, and the bispecific peptide synergizes with radiotherapy to further enhance the antitumor immune response.
RESUMEN
In recent years, gel-based ion conductor has been widely considered in wearable electronics because of the favorable flexibility and conductivity. However, it is of vital importance, yet rather challenging to adapt the gel for underwater and dry conditions. Herein, an anti-swelling and anti-drying, intrinsic conductor eutectogel is designed via a one-step radical polymerization of acrylic acid and 2, 2, 2trifluoroethyl methacrylate in binary deep eutectic solvents (DESs) medium. On the one hand, the synergistic effects of hydrophilic/hydrophobic heteronetworks can elicit the integrity stability of eutectogel in liquid environment. It is proved that both the mechanical property and conductivity are maintained after immersing in different salt, alkaline and acid solution and organic solvent for one month. On the other hand, the eutectogel inherits well conductivity (93 mS/m), anti-drying and antibacterial properties from DESs. Based on the above features, the resulting eutectogel can be assembled as smart sensor for stable information transmission in air and underwater with fast response time (1 s), high sensitivity (Gauge factor = 1.991) and long-time reproducibility (500 cycles, 70 % strain). Considering the simple preparation and integration of multiple functions, the binary cooperative complementary principle can provide insights into the development of next-generation conductive soft materials.
RESUMEN
GZR18 is a novel analog of glucagon-like peptide-1 (GLP-1). This study evaluates the pharmacology, pharmacokinetics, and efficacy of GZR18, and its potential for the treatment of Type 2 diabetes mellitus (T2DM). In vitro pharmacology and activity of GZR18 were characterized by a binding assay of GZR18 using human serum albumin (HSA), an activation assay in human GLP-1 receptor-expressing cell lines, and its effect on glucose-stimulated insulin secretion (GSIS) in primary mice islets. Pharmacokinetic profiling was performed in Sprague Dawley rats and cynomolgus monkeys, and efficacy evaluated using GZR18 single or repeated doses in db/db mice. GZR18 showed similar binding affinity for HSA and GLP-1 receptor compared with semaglutide and liraglutide. GZR18 increased GSIS, which was confirmed by dynamic islet perifusion and fluorescence imaging using PKZnR-5 for real-time detection. In cynomolgus monkeys, the average GZR18 maximal concentration was 527 nmol L-1, the terminal half-life (T1/2) was 61.3 h, and the time to maximum concentration was 14 h. Single-dose GZR18 lowered blood glucose levels and reduced body weight over 72 h in db/db mice. GZR18 successive administration (every three days for 33 days, i.e. 11 doses) lowered nonfasting and fasting blood glucose levels (p < 0.05 versus control) and glycated hemoglobin, following the 11th dose. Food and water consumption in db/db mice was lowered following repeated doses of GZR18 (p < 0.05 versus control), without a reduction in body weight. These results demonstrate the potential of GZR18 as a long-acting GLP-1 analog for the treatment of T2DM.
Asunto(s)
Diabetes Mellitus Experimental , Diabetes Mellitus Tipo 2 , Animales , Glucemia/metabolismo , Peso Corporal , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Péptido 1 Similar al Glucagón/farmacología , Receptor del Péptido 1 Similar al Glucagón/metabolismo , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Insulina/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Modelos Animales , Ratas , Ratas Sprague-DawleyRESUMEN
BACKGROUND: Metastasis is the leading cause of mortality in human cancers, including esophageal squamous cell carcinoma (ESCC). As a pro-inflammatory cytokine, IL-32 was reported to be a poor prognostic factor in many cancers. However, the role of IL-32 in ESCC metastasis remains unknown. METHODS: ESCC cells with ectopic expression or knockdown of IL-32 were established and their effects on cell motility were detected. Ultracentrifugation, Transmission electron microscopy and Western blot were used to verify the existence of extracellular vesicle IL-32 (EV-IL-32). Coculture assay, immunofluorescence, flow cytometry, and in vivo lung metastasis model were performed to identify how EV-IL-32 regulated the crosstalk between ESCC cells and macrophages. RESULTS: Here, we found that IL-32 was overexpressed and positively correlated to lymph node metastasis of ESCC. IL-32 was significantly higher in the tumor nest compared with the non-cancerous tissue. We found that IL-32ß was the main isoform and loaded in EV derived from ESCC cells. The shuttling of EV-IL-32 derived from ESCC cells into macrophages could promote the polarization of M2 macrophages via FAK-STAT3 pathway. IL-32 overexpression facilitated lung metastasis and was positively correlated with the proportion of M2 macrophages in tumor microenvironment. CONCLUSIONS: Taken together, our results indicated that EV-IL-32 derived from ESCC cell line could be internalized by macrophages and lead to M2 macrophage polarization via FAK-STAT3 pathway, thus promoting the metastasis of ESCC. These findings indicated that IL-32 could serve as a potential therapeutic target in patients with ESCC.
Asunto(s)
Neoplasias Esofágicas , Carcinoma de Células Escamosas de Esófago , Vesículas Extracelulares , Quinasa 1 de Adhesión Focal , Neoplasias Pulmonares , Macrófagos , Factor de Transcripción STAT3 , Línea Celular Tumoral , Neoplasias Esofágicas/metabolismo , Neoplasias Esofágicas/patología , Carcinoma de Células Escamosas de Esófago/metabolismo , Carcinoma de Células Escamosas de Esófago/patología , Vesículas Extracelulares/metabolismo , Quinasa 1 de Adhesión Focal/metabolismo , Humanos , Interleucinas/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Macrófagos/metabolismo , Factor de Transcripción STAT3/metabolismo , Microambiente TumoralRESUMEN
Strategies boosting both innate and adaptive immunity have great application prospects in cancer immunotherapy. Antibodies dual blocking the innate checkpoint CD47 and adaptive checkpoint PD-L1 or TIGIT could achieve durable anti-tumor effects. However, a small molecule dual blockade of CD47/SIRPα and TIGIT/PVR pathways has not been investigated. Here, an elevated expression of CD47 and PVR was observed in tumor tissues and cell lines analyzed with the GEO datasets and by flow cytometry, respectively. Compounds approved by the FDA were screened with the software MOE by docking to the potential binding pockets of SIRPα and PVR identified with the corresponding structural analysis. The candidate compounds were screened by blocking and MST binding assays. Azelnidipine was found to dual block CD47/SIRPα and TIGIT/PVR pathways by co-targeting SIRPα and PVR. In vitro, azelnidipine could enhance the macrophage phagocytosis when co-cultured with tumor cells. In vivo, azelnidipine alone or combined with irradiation could significantly inhibit the growth of MC38 tumors. Azelnidipine also significantly inhibits the growth of CT26 tumors, by enhancing the infiltration and function of CD8+ T cell in tumor and systematic immune response in the tumor-draining lymph node and spleen in a CD8+ T cell dependent manner. Our research suggests that the anti-hypertensive drug azelnidipine could be repositioned for cancer immunotherapy.
Asunto(s)
Ácido Azetidinocarboxílico/análogos & derivados , Dihidropiridinas/farmacología , Reposicionamiento de Medicamentos/métodos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Inmunoterapia/métodos , Neoplasias/terapia , Animales , Ácido Azetidinocarboxílico/farmacología , Antígeno CD47/antagonistas & inhibidores , Bloqueadores de los Canales de Calcio/farmacología , Línea Celular Tumoral , Cricetinae , Modelos Animales de Enfermedad , Humanos , Inmunidad Innata , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Terapia Molecular Dirigida , Neoplasias/inmunología , Neoplasias/metabolismo , Neoplasias/patología , Receptores Inmunológicos/antagonistas & inhibidores , Receptores Virales/antagonistas & inhibidores , Linfocitos T/efectos de los fármacosRESUMEN
AIM: This study is designed to investigate whether or not AMP-activated protein kinase α1 (AMPKα1) is required for natural product berberine (BBR) to improve glucose and lipid metabolism in HepG2 cells. METHODS: AMPKα1 knocked-out (KO, AMPKα1-/- ) cells were obtained by co-transfection of the CRISPR/Cas9 KO and HDR (homology-directed repair) plasmid into HepG2 cells, as well as subsequent screen with puromycin. The expression levels of target proteins or mRNAs were determined by western blot or real-time RT-PCR, respectively. Cellular AMPK activity, glucose consumption, lactate release, glucose production, and lipid accumulation were determined by kits. RESULTS: The results showed that the AMPKα1 gene was successfully KO in HepG2 cells. In AMPKα1-/- cells, the protein expression of AMPKα1 and phosphorylated-AMPKα1 (p-AMPKα1) disappeared, the level of total AMPKα declined to about 45-50% of wild type (p < 0.01), while p-AMPKα level and AMPK activity were reduced to less than 10% of wild type (p < 0.001). BBR increased p-AMPKα1, p-AMPKα, AMPK activity, and stimulated glucose consumption, lactate release, inhibited glucose production in wild type HepG2 cells (p < 0.05 or p < 0.01). BBR also reduced intracellular lipid accumulation and suppressed the expression of lipogenic genes in oleic acid (OA) treated wild type HepG2 cells (p < 0.05 or p < 0.01). In AMPKα1-/- HepG2 cells, the stimulating effects of BBR on p-AMPKα1, p-AMPKα, AMPK activity, and its improving effects on glucose and lipid metabolism were completely abolished. CONCLUSION: Our study proves that AMPKα1 plays a critical role for BBR to improve glucose and lipid metabolism in HepG2 cells. Our results will provide new information to further understand the molecular mechanisms of BBR.
RESUMEN
Adenosine 5'-monophosphate-activated protein activated protein kinase (AMPK), a heterotrimeric complex, is an important kinase to regulate glycolipid metabolism and energy balance involved in a variety physiological processes in human body. Many research indicated that the function and activity of AMPK were closely related to inflammation, diabetes and cancers. Recent reports show that inhibition of metformin (a first-line drug) on hepatic glucose in patients with hyperglycemia is associated with AMPK pathway, suggesting that targeting AMPK may be one of the effective strategies for the prevention and treatment of a variety of chronic diseases. Here, we review research progress on the structure, activation and regulation of AMPK in glycolipid metabolism to provide an insight into the basic and clinical research of diabetes therapy.